Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 13, 2014 - Issue 9
Submit an article Journal homepage
607
Views
24
CrossRef citations to date
0
Altmetric
Original Research

Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program

Daniel CastellanoUniversity Hospital 12 de Octubre, Medical Oncology Department, Urooncology Unit (I+12 Research Institute), Avda. de Cordoba, s/n, 28041 Madrid, Spain
,
Luis M Antón AparicioHospital Juan Canalejo, Medical Oncology Department, c/Xubias de Arriba, 84, 15006 La Coruña, Spain
,
Emilio EstebanHospital General de Asturias, Medical Oncology Department, c/Julián Clavería, s/n, 33006 Oviedo, Spain
,
Alfredo Sánchez-HernándezHospital Provincial de Castellón, Medical Oncology Department, Av. Doctor Clara, 19, 12002 Castellón de la Plana, Spain
,
Jose Ramón GermàHospital Duran i Reynals, ICO, Medical Oncology Department, Av. de la Gran Via de l’Hospitalet, 199 – 203, 08908 Barcelona, Spain
,
Norberto BatistaHospital Universitario de Canarias, Medical Oncology Department, Ctra. Cuesta-Taco, s/n, 38320 Tenerife, Spain
,
Pablo MarotoHospital de la Santa Creu i Sant Pau, Medical Oncology Department, Carrer Sant Quintí, 89, 08026 Barcelona, Spain
,
Begoña Pérez-ValderramaHospital Universitario Virgen del Rocío, Medical Oncology Department, Avda. Manuel Siurot, s/n, 41013 Seville, Spain
,
Raquel LuqueHospital Virgen de las Nieves, Medical Oncology Department, Avda de las Fuerzas Armadas, 2, 18014 Granada, Spain
,
María José Méndez-VidalHospital Univ. Reina Sofia, Medical Oncology Department, Avda. Menéndez Pidal, s/n, 14004 Córdoba, Spain
& on behalf of the cabazitaxel EAP study show all
Pages 1165-1173 | Published online: 07 Jul 2014

Bibliography

  • Vrignaud P, Semiond D, Lejeune P, et al. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clin Cancer Res 2013;19:2973-83
  • Darshan MS, Loftus MS, Thadani-Mulero M, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 2011;71:6019-29
  • Zhu ML, Horbinski CM, Garzotto M, et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 2010;70:7992-8002
  • de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54
  • Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205
  • Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011;47:8-32
  • National Health Institute. National Cancer Institute Common Terminology Criteria for Adverse Events v4.0. NIH publication; 29 A.D. Report No.: #09-7473. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_30 [Last accessed: 20 June 2014]
  • Brown E. Medical Dictionary for Regulatory Activities (MedDRA®), in pharmacovigilance. In: Mann RD, Andrews EB, editors. Pharmacovigilance. 2nd edition. John Wiley & Sons, Ltd, Chichester, UK; 2007. Available from: http://www.meddra.org [Last accessed: 20 June 2014]
  • De Velasco G, Anton Aparicio L, Esteban E. Cabazitaxel in patients with advanced CRPC after docetaxel failure: results of expanded program access (EAP) in Spain: safety and efficacy. J Clin Oncol 2012;30:abstract #e15149
  • National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: cancer-related fatigue. In: National Comprehensive Cancer Network, editor. Version 1.2013. ed Fort Washington, Pa: 2013. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#fatigue. Accessed May 2013
  • Di Lorenzo G, D’Aniello C, Buonerba C, et al. Peg-filgrastim and cabazitaxel in prostate cancer patients. Anticancer Drugs 2013;24:84-9
  • Sperlich C, Saad F. Optimal management of patients receiving cabazitaxel-based chemotherapy. Can Urol Assoc J 2013;7:S18-24
  • Bahl A, Masson S, Malik Z. Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): interim safety and quality-of-life (QOL) data from the U.K. early access program (NCT01254279). J Clin Oncol 2012;30:abstract #44
  • Bracarda S, Gernone A, Gasparro D, et al. Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. Future Oncol 2014;10(6):975-83
  • Heck MM, Hoppner M, Horn T, et al. [Compassionate use of abiraterone and cabazitaxel: first experiences in docetaxel-pretreated castration-resistant prostate cancer patients]. Urologe A 2012;51:390-7
  • Heidenreich A, Scholz HJ, Rogenhofer S, et al. Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. Eur Urol 2013;63:977-82
  • Sridhar SS, Winquist E, Hubay S. Cabazitaxel early access program (EAP) - Canadian interim results: safety, QOL, and utility values in metastatic castration resistant prostate cancer (mCRPC). Ann Oncol 2012;23:abstract #960
  • Wissing MD, van Oort IM, Gerritsen WR, et al. Cabazitaxel in patients with metastatic castration-resistant prostate cancer: results of a compassionate use program in the Netherlands. Clin Genitourin Cancer 2013;11:238-50
  • Heidenreich A, Bracarda S, Mason M, et al. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. Eur J Cancer 2014;50:1090-9
  • Armstrong AJ, Garrett-Mayer ES, Yang YC, et al. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007;13:6396-403
  • Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21:1232-7
  • Bahl A, Oudard S, Tombal B, et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol 2013;24:2402-8

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.